OnKure Therapeutics, Inc.
OKURNasdaq
$4.20
↑ +2.4%Jul 17 close · end-of-day
Price
1Y↑ +68.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$57.4M
Enterprise Value
-$134.7M
P/E
—
P/S
—
P/B
0.3
EV/EBITDA
—
PEG
—
FCF Yield
-88.4%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$58.7M
Free Cash Flow (TTM)
-$50.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-31.9%
ROIC
—
Debt / Equity
—
Net Cash
$192.1M
Return 1Y
+76.5%
Company profile
We are a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small-molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
- CEO
- Nicholas A. Saccomano
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Colorado
- Website
- onkuretherapeutics.com
Management & directors
- Leverone Jason A.Chief Financial Officer
- Saccomano Nicholas APresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
OKUR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.11↓ -6.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$19.6M | -$39.8M | -$53.8M | -$36.9M | -$54.4M | -$63.0M |
| Net income | -$19.5M | -$39.8M | -$52.0M | -$35.3M | -$52.7M | -$59.5M |
| Diluted EPS | -$9.60 | -$2.19 | -$2.12 | -$124.41 | -$15.28 | -$4.40 |
| Operating cash flow | -$18.5M | -$38.0M | -$47.4M | -$34.5M | -$51.1M | -$51.8M |
| Free cash flow | -$18.6M | -$38.2M | -$47.7M | -$34.8M | -$51.2M | -$51.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$14.3M | -$11.5M | -$18.7M | -$17.0M | -$16.3M | -$15.5M | -$14.1M | -$15.6M |
| Net income | -$14.1M | -$11.6M | -$17.4M | -$15.9M | -$15.4M | -$14.7M | -$13.5M | -$15.2M |
| Diluted EPS | -$44.82 | -$36.55 | $96.46 | -$1.19 | -$1.14 | -$1.09 | -$0.98 | -$1.11 |
| Operating cash flow | -$6.5M | -$10.7M | -$23.4M | -$14.0M | -$13.3M | -$13.0M | -$11.5M | -$12.9M |
| Free cash flow | -$6.5M | -$10.7M | -$23.4M | -$14.0M | -$13.3M | -$13.0M | -$11.5M | -$12.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 15, 2026
Apr 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-22 | Leverone Jason A.· Chief Financial Officer | Sale | 303 | $4.40 | $1,332.08 | filing |
| 2026-06-22 | Saccomano Nicholas A· President and CEO | Sale | 86 | $4.40 | $378.08 | filing |
| 2026-03-23 | Leverone Jason A.· Chief Financial Officer | Sale | 301 | $4.16 | $1,251.11 | filing |
| 2026-03-23 | Saccomano Nicholas A· President and CEO | Sale | 86 | $4.16 | $357.46 | filing |
| 2025-12-31 | Mathers Edward T | Award | 3,911 | $0.00 | $0.00 | filing |
| 2025-12-31 | Manke Isaac | Award | 5,258 | $0.00 | $0.00 | filing |
| 2025-12-22 | Leverone Jason A.· Chief Financial Officer | Sale | 302 | $2.97 | $896.25 | filing |
| 2025-12-22 | Saccomano Nicholas A· President and CEO | Sale | 87 | $2.97 | $258.19 | filing |
| 2025-09-30 | Manke Isaac | Award | 5,545 | $0.00 | $0.00 | filing |
| 2025-09-30 | Mathers Edward T | Award | 4,125 | $0.00 | $0.00 | filing |
| 2025-09-22 | Leverone Jason A.· Chief Financial Officer | Sale | 303 | $2.62 | $794.92 | filing |
| 2025-09-22 | Saccomano Nicholas A· President and CEO | Sale | 88 | $2.62 | $230.87 | filing |
| 2025-06-30 | Mathers Edward T | Award | 4,694 | $0.00 | $0.00 | filing |
| 2025-06-30 | Manke Isaac | Award | 6,311 | $0.00 | $0.00 | filing |
| 2025-06-23 | Leverone Jason A.· Chief Financial Officer | Sale | 303 | $2.38 | $722.41 | filing |
| 2025-06-23 | Saccomano Nicholas A· President and CEO | Sale | 88 | $2.38 | $209.81 | filing |
Latest 16 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.